Gavin Liu is an associate in the Silicon Valley office of Latham & Watkins and a member of the Technology Transactions Practice.
Mr. Liu advises public and emerging life science companies on various commercial and intellectual property transactional matters including:
- Collaboration, co-development, and profit-sharing agreements
- Commercial licenses
- Licenses with universities, hospitals, non-profit entities
- Intellectual property asset purchase agreements, carve-out transactions, and related agreements
- Joint ventures
- M&A transactions
- Capital markets transactions
- Manufacturing, supply, and distribution arrangements
- Strategic counseling
Mr. Liu maintains an active pro bono practice, which includes representing individuals seeking asylum in the United States. He is a member of Latham's Parent Lawyers Group and Asian & MIddle Eastern Lawyers Group.
While in law school, Mr. Liu served on the Editorial Board of the Berkeley Technology and Law Journal. He is also an alumni of the Samuelson Law, Technology, and Public Policy Clinic.
Prior to joining Latham, Mr. Liu was a junior specialist at the Keck Center for Integrative Neuroscience, at the University of California, San Francisco, where he implemented an optogenetics model for studying basal ganglia circuitry in songbirds.
Mr. Liu’s experience includes advising:
- Allergan PLC in the divestiture of its generics business to Teva Pharmaceuticals
- Confluence Life Sciences in its sale to Aclaris Therapeutics
- Sofregen in a purchase of assets related to Allergan’s “Seri Scaffold” surgical scaffold product
- Sienna Biopharmaceuticals in its initial public offering
- Novan in its initial public offering
- Aimmune in its initial public offering
- Underwriter in Calyxt, Inc. initial public offering
- Agile Therapeutics, Akebia Therapeutics, Tetraphase Pharmaceuticals, Spring Bank Pharmaceuticals, and Corium, Inc. in their follow-on offerings.
- Corvus Pharmaceuticals in an academic in-license from Monash University
- Anivive Lifesciences in a commercial in-license from Karyopharm Therapeutics for verdinexor for animal indications
- Ascendis Pharma A/S in its formation of VISEN Pharmaceuticals, a joint venture with a syndicate of a Chinese investor, and license to VISEN of rights to develop and commercialize Ascendis’s TransCon products in the People’s Republic of China
- Prothena Corporation in its collaboration agreement with Celgene Corporation focused on researching, developing, and commercializing novel therapies for neurodegenerative disease.
- Mapi Pharma in its exclusive license to Mylan N.V. of its long-acting glatiramer acetate depot product.